BE2014C026I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2014C026I2 BE2014C026I2 BE2014C026C BE2014C026C BE2014C026I2 BE 2014C026 I2 BE2014C026 I2 BE 2014C026I2 BE 2014C026 C BE2014C026 C BE 2014C026C BE 2014C026 C BE2014C026 C BE 2014C026C BE 2014C026 I2 BE2014C026 I2 BE 2014C026I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/76—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and etherified hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C271/38—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0122201A GB0122201D0 (en) | 2001-09-14 | 2001-09-14 | Medicinal compounds |
GB0126997A GB0126997D0 (en) | 2001-11-09 | 2001-11-09 | Medicinal Compounds |
PCT/GB2002/004140 WO2003024439A1 (en) | 2001-09-14 | 2002-09-11 | Phenethanolamine derivatives for treatment of respiratory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2014C026I2 true BE2014C026I2 (pl) | 2021-11-22 |
Family
ID=26246542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2014C026C BE2014C026I2 (pl) | 2001-09-14 | 2014-04-25 |
Country Status (31)
Country | Link |
---|---|
US (6) | USRE44874E1 (pl) |
EP (2) | EP2042168B1 (pl) |
JP (1) | JP4191034B2 (pl) |
KR (2) | KR20090057477A (pl) |
CN (3) | CN103288793B (pl) |
AR (2) | AR036874A1 (pl) |
AT (1) | ATE417606T1 (pl) |
AU (1) | AU2002326026B2 (pl) |
BE (1) | BE2014C026I2 (pl) |
BR (1) | BRPI0212455B8 (pl) |
CA (1) | CA2458534C (pl) |
CO (1) | CO5560552A2 (pl) |
CY (3) | CY1109422T1 (pl) |
DE (1) | DE60230425D1 (pl) |
DK (2) | DK2042168T3 (pl) |
ES (2) | ES2438985T3 (pl) |
FR (1) | FR14C0028I2 (pl) |
HK (1) | HK1066479A1 (pl) |
HU (2) | HU228508B1 (pl) |
IL (2) | IL160595A0 (pl) |
LU (1) | LU92439I2 (pl) |
MX (1) | MXPA04002405A (pl) |
MY (1) | MY129422A (pl) |
NO (2) | NO333813B1 (pl) |
NZ (1) | NZ531651A (pl) |
PL (2) | PL393155A1 (pl) |
PT (2) | PT2042168E (pl) |
RU (2) | RU2312854C2 (pl) |
SI (2) | SI1425001T1 (pl) |
TW (1) | TWI299661B (pl) |
WO (1) | WO2003024439A1 (pl) |
Families Citing this family (167)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
CN103288793B (zh) * | 2001-09-14 | 2015-09-23 | 葛兰素集团有限公司 | 治疗呼吸疾病的苯乙醇胺衍生物 |
JP2005507881A (ja) | 2001-09-17 | 2005-03-24 | グラクソ グループ リミテッド | 乾燥粉末医薬製剤 |
TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
JP2005527618A (ja) | 2002-05-28 | 2005-09-15 | セラヴァンス インコーポレーテッド | アルコキシアリールβ2アドレナリン作動性レセプターアゴニスト |
GB0220730D0 (en) * | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
WO2004037773A1 (en) | 2002-10-28 | 2004-05-06 | Glaxo Group Limited | Phenethanolamine derivative for the treatment of respiratory diseases |
GB0303396D0 (en) * | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds |
PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
WO2004101525A1 (en) | 2003-05-08 | 2004-11-25 | Theravance, Inc. | Crystalline form of aryl aniline beta-2 adrenergic receptor agonist |
TW200510277A (en) | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
US7067541B2 (en) | 2003-06-04 | 2006-06-27 | Pfizer Inc | 2-amino-pyridine derivatives useful for the treatment of diseases |
WO2004108675A1 (en) * | 2003-06-04 | 2004-12-16 | Pfizer Limited | 2-amino-pyridine derivatives as beta-2 adrenoreceptor agonists |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
TW200526547A (en) | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
GB0329182D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Chemical compounds |
TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
US20080039495A1 (en) | 2004-06-03 | 2008-02-14 | Linsell Martin S | Diamine Beta2 Adrenergic Receptor Agonists |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
EP1778638A1 (en) | 2004-07-21 | 2007-05-02 | Theravance, Inc. | Diaryl ether beta2 adrenergic receptor agonists |
GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
JP2008510015A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス, インコーポレーテッド | β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
US7566785B2 (en) * | 2004-09-10 | 2009-07-28 | Theravance, Inc. | Amidine substituted aryl aniline compounds |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
ATE517908T1 (de) | 2005-01-10 | 2011-08-15 | Glaxo Group Ltd | Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände |
TWI389690B (zh) | 2005-03-25 | 2013-03-21 | Glaxo Group Ltd | 新穎化合物(一) |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
CA2618089A1 (en) | 2005-08-08 | 2007-02-15 | Argenta Discovery Ltd. | Bicyclo[2.2.]hept-7-ylamine derivatives and their uses |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
GB0520794D0 (en) * | 2005-10-12 | 2005-11-23 | Innovata Biomed Ltd | Inhaler |
PT2532679T (pt) | 2005-10-21 | 2017-07-18 | Novartis Ag | Anticorpos humanos contra il13 e utilizações terapêuticas |
PE20071068A1 (es) | 2005-12-20 | 2007-12-13 | Glaxo Group Ltd | Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3 |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
KR20090003349A (ko) | 2006-04-20 | 2009-01-09 | 글락소 그룹 리미티드 | 화합물 |
SI2013211T1 (sl) | 2006-04-21 | 2012-07-31 | Novartis Ag | Purinski derivati za uporabo kot agonisti receptorja adenozina A A |
GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
PE20080943A1 (es) | 2006-06-23 | 2008-09-27 | Smithkline Beecham Corp | Sal toluenosulfonato de 4-{[6-cloro-3-({[(2-cloro-3-fluorofenil)amino]carbonil}amino)-2-hidroxifenil]sulfonil}-1-piperazinacarboxilato de 1,1-dimetiletilo como antagonista del receptor de il-8 |
US20090325952A1 (en) | 2006-08-01 | 2009-12-31 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
PL2104535T3 (pl) | 2007-01-10 | 2011-05-31 | Irm Llc | Związki i kompozycje jako inhibitory proteazy aktywujące kanały |
GB0702458D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
CN101646437A (zh) | 2007-02-09 | 2010-02-10 | Irm责任有限公司 | 作为通道活化蛋白酶抑制剂的化合物和组合物 |
PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
KR20100005730A (ko) | 2007-05-07 | 2010-01-15 | 노파르티스 아게 | 유기 화합물 |
EA017919B1 (ru) | 2007-12-10 | 2013-04-30 | Новартис Аг | Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов |
WO2009087224A1 (en) | 2008-01-11 | 2009-07-16 | Novartis Ag | Pyrimidines as kinase inhibitors |
EP2096105A1 (en) * | 2008-02-28 | 2009-09-02 | Laboratorios Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor |
US20110160249A1 (en) | 2008-05-23 | 2011-06-30 | Schaab Kevin Murray | 5-lipoxygenase-activating protein inhibitor |
JP5502858B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | Pi3キナーゼの阻害剤として有用な4−カルボキサミドインダゾール誘導体 |
CN102112130A (zh) | 2008-06-10 | 2011-06-29 | 诺瓦提斯公司 | 作为上皮钠通道阻滞剂的吡嗪衍生物 |
JP2011524896A (ja) | 2008-06-18 | 2011-09-08 | アストラゼネカ・アクチエボラーグ | 呼吸器障害の処置用のベータ2−アドレナリン受容体アゴニストとして作用するベンズオキサジノン誘導体 |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
PL2379507T3 (pl) | 2008-12-30 | 2014-03-31 | Pulmagen Therapeutics Inflammation Ltd | Związki sulfonamidu do leczenia zaburzeń układu oddechowego |
WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
WO2010097115A1 (en) | 2009-02-26 | 2010-09-02 | Glaxo Group Limited | Pharmaceutical formulations comprising 4-{(1r)-2- [(6-{2-[(2,6-dichlorobenzyl)oxy] ethoxy}hexyl)amino]-1-hydroxyethyl}-2- (hydroxymethyl)phenol |
WO2010097114A1 (en) * | 2009-02-26 | 2010-09-02 | Glaxo Group Limited | Novel combination of therapeutic agents |
EP2406255B1 (en) | 2009-03-09 | 2015-04-29 | Glaxo Group Limited | 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases |
JP2012520257A (ja) | 2009-03-10 | 2012-09-06 | グラクソ グループ リミテッド | Ikk2阻害剤としてのインドール誘導体 |
JP2012520845A (ja) | 2009-03-17 | 2012-09-10 | グラクソ グループ リミテッド | Itk阻害剤として使用されるピリミジン誘導体 |
US20120029054A1 (en) | 2009-03-19 | 2012-02-02 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA) |
EP2408458A1 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
CN102439151A (zh) | 2009-03-19 | 2012-05-02 | 默沙东公司 | 使用短干扰核酸(siNA)的RNA干扰介导的BTB和CNC同系物1,碱性亮氨酸拉链转录因子1(Bach1)基因表达的抑制 |
EP2408916A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20120022142A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
JP2012521762A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた神経成長因子β鎖(NGFβ)遺伝子発現のRNA干渉媒介性阻害 |
US20120004282A1 (en) | 2009-03-27 | 2012-01-05 | Merck Sharp & Dohme Corp, | RNA Interference Mediated Inhibition of the Intercellular Adhesion Molecule 1 (ICAM-1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20120010272A1 (en) | 2009-03-27 | 2012-01-12 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
EP2411520A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010122089A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | N-pyrazolyl carboxamides as crac channel inhibitors |
EP2421834A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
ES2876933T3 (es) | 2009-04-30 | 2021-11-15 | Glaxo Group Ltd | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas |
WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
PL2987490T3 (pl) | 2009-07-15 | 2017-12-29 | Theravance Biopharma R&D Ip, Llc | Postacie krystaliczne wolnej zasady związku bifenylowego |
CN102665715A (zh) | 2009-10-22 | 2012-09-12 | 沃泰克斯药物股份有限公司 | 治疗囊性纤维化和其他慢性疾病的组合物 |
GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
GB0921075D0 (en) * | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
EP2507226A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Novel compounds |
EP2507223A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
US20120238571A1 (en) | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Indazole derivatives as pi 3-kinase |
EP2512438B1 (en) | 2009-12-16 | 2017-01-25 | 3M Innovative Properties Company | Formulations and methods for controlling mdi particle size delivery |
WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
KR101004750B1 (ko) * | 2010-08-16 | 2011-01-04 | 주식회사 행림종합 건축사사무소 | 피막보호형 보강 단열패널 및 이를 이용한 노출형 외단열방수공법 |
EP2611423B2 (en) | 2010-08-31 | 2022-09-21 | GlaxoSmithKline Intellectual Property Development Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
AU2014268195B2 (en) * | 2010-08-31 | 2015-11-12 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
WO2012032067A1 (en) | 2010-09-08 | 2012-03-15 | Glaxo Group Limited | Polymorphs and salts of n- [5- [4- (5- { [(2r,6s) -2, 6 - dimethyl - 4 -morpholinyl] methyl} - 1, 3 - oxazol - 2 - yl) - 1h- inda zol-6-yl] -2- (methyloxy) - 3 - pyridinyl] methanesulfonamide |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
US9149462B2 (en) | 2010-10-21 | 2015-10-06 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
EP2630126B1 (en) | 2010-10-21 | 2015-01-07 | Glaxo Group Limited | Pyrazole compounds acting against allergic, immune and inflammatory conditions |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
EP2749284A3 (en) | 2011-02-17 | 2014-08-20 | Cipla Limited | Combination of glycopyrronium and carmoterol |
AP2013007103A0 (en) | 2011-02-25 | 2013-09-30 | Irm Llc | Compounds and compositions as TRK inhibitors |
US20140005188A1 (en) | 2011-03-11 | 2014-01-02 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
JP2014518894A (ja) | 2011-06-08 | 2014-08-07 | グラクソ グループ リミテッド | ウメクリジニウムを含む乾燥粉末インヘラー組成物 |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
US9056867B2 (en) | 2011-09-16 | 2015-06-16 | Novartis Ag | N-substituted heterocyclyl carboxamides |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
ES2558457T3 (es) | 2011-09-16 | 2016-02-04 | Novartis Ag | Compuestos heterocíclicos para el tratamiento de fibrosis quística |
GB201116641D0 (en) | 2011-09-27 | 2011-11-09 | Glaxo Group Ltd | Novel compounds |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
ES2814336T3 (es) | 2012-04-13 | 2021-03-26 | Glaxosmithkline Ip Dev Ltd | Partículas de agregado |
GB201207406D0 (en) | 2012-04-27 | 2012-06-13 | Glaxo Group Ltd | Novel compounds |
TWI593678B (zh) | 2012-04-27 | 2017-08-01 | 葛蘭素集團有限公司 | 作為類視色素相關孤兒受體γ(RORγ)調節劑之化合物、其醫藥組合物及用途 |
EA036153B1 (ru) | 2012-07-05 | 2020-10-06 | Арвен Айлак Санайи Ве Тиджарет А.С. | Фармацевтическая композиция для ингаляции, упакованная дозированная форма, капсула, способ лечения обструктивных заболеваний дыхательных путей и фармацевтический набор |
US20150239862A1 (en) * | 2012-09-13 | 2015-08-27 | Perrigo Api Ltd. | Process for the preparation of vilanterol and intermediates thereof |
GB201222679D0 (en) | 2012-12-17 | 2013-01-30 | Glaxo Group Ltd | Pharmaceutical combination products |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
JP6560986B2 (ja) | 2013-03-15 | 2019-08-14 | ヴェローナ ファーマ ピーエルシー | 複合製剤 |
EP3057587A1 (en) | 2013-10-17 | 2016-08-24 | GlaxoSmithKline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
JP6475707B2 (ja) | 2013-10-17 | 2019-02-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 呼吸器疾患の治療のためのpi3k阻害剤 |
CN104744270A (zh) * | 2013-12-26 | 2015-07-01 | 成都伊诺达博医药科技有限公司 | 长效β2受体激动剂维兰特罗的合成新方法 |
CN104744271B (zh) * | 2013-12-26 | 2016-08-31 | 成都伊诺达博医药科技有限公司 | 一种合成维兰特罗的新工艺 |
MX2016013812A (es) | 2014-04-24 | 2017-03-09 | Novartis Ag | Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa. |
CA2945069A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2015162461A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
MX2016014859A (es) | 2014-05-12 | 2017-06-27 | Glaxosmithkline Intellectual Property (No 2) Ltd | Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas. |
ES2959699T3 (es) | 2014-05-28 | 2024-02-27 | Glaxosmithkline Ip Dev Ltd | Furoato de fluticasona en el tratamiento de la EPOC |
EP2957552B1 (en) | 2014-06-16 | 2020-01-22 | Arven Ilac Sanayi Ve Ticaret A.S. | Vilanterol formulations |
EP2957553A1 (en) | 2014-06-16 | 2015-12-23 | Arven Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical formulations of vilanterol |
MA39288A (fr) | 2014-06-16 | 2015-12-23 | Arven Ilac Sanayi Ve Ticaret As | Formulations pharmaceutiques comprenant du vilanterol |
TR201407010A2 (tr) | 2014-06-16 | 2015-12-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Vilanterol formülasyonları. |
MA40444A (fr) | 2014-07-09 | 2017-05-17 | Arven Ilac Sanayi Ve Ticaret As | Procédé de préparation de formulations de poudre sèche |
ES2672383T3 (es) | 2014-07-09 | 2018-06-14 | Arven Ilac Sanayi Ve Ticaret A.S. | Un procedimiento de preparación de las formulaciones de inhalación |
ES2701525T3 (es) | 2014-07-09 | 2019-02-22 | Arven Ilac Sanayi Ve Ticaret As | Un procedimiento para la preparación de formulaciones para inhalación |
WO2017001907A1 (en) | 2015-06-29 | 2017-01-05 | Teva Pharmaceuticals International Gmbh | Biocatalytic processes for the preparation of vilanterol |
GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
CN107188813B (zh) * | 2016-03-14 | 2019-04-26 | 益方生物科技(上海)有限公司 | 苯乙醇胺衍生物及其制备方法和用途 |
US20190161480A1 (en) | 2016-08-08 | 2019-05-30 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
PT110209B (pt) * | 2017-07-19 | 2021-05-17 | Hovione Farm Sa | Formas polimórficas de trifenatato de vilanterol e processos para a preparação das mesmas. |
GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
RU2751162C1 (ru) | 2018-03-14 | 2021-07-08 | Асахи Касеи Кабусики Кайся | Способ получения мономера, содержащего сульфогруппу |
IT201800004492A1 (it) * | 2018-04-13 | 2019-10-13 | Procedimento per la sintesi di beta-amminoalcoli otticamente attivi | |
WO2020047225A1 (en) | 2018-08-30 | 2020-03-05 | Theravance Biopharma R&D Ip, Llc | Methods for treating chronic obstructive pulmonary disease |
CN109574861A (zh) * | 2019-01-22 | 2019-04-05 | 安徽德信佳生物医药有限公司 | 一种维兰特罗三苯乙酸盐的结晶方法 |
CN111807973B (zh) * | 2019-04-10 | 2021-04-30 | 上海谷森医药有限公司 | 维兰特罗及其盐的制备方法 |
WO2020237151A1 (en) | 2019-05-23 | 2020-11-26 | Huang Cai Gu | Inhalable formulation of a solution containing vilanterol trifenatate and umeclidinium bromide |
MX2021015133A (es) | 2019-06-10 | 2022-01-24 | Novartis Ag | Derivado de piridina y pirazina para el tratamiento de la fibrosis quistica, enfermedad pulmonar obstructiva cronica y bronquiectasia. |
MX2022002374A (es) | 2019-08-28 | 2022-03-29 | Novartis Ag | Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades. |
US11083693B1 (en) | 2020-01-20 | 2021-08-10 | Cai Gu Huang | Liposome formulation of vilanterol trifenatate |
IL300069A (en) | 2020-07-27 | 2023-03-01 | Inke Sa | A method for the purification of vilanterol tripentate |
WO2023118833A1 (en) | 2021-12-22 | 2023-06-29 | Hovione Scientia Limited | Process to prepare vilanterol trifenatate |
CN115286491B (zh) * | 2022-08-31 | 2023-09-15 | 山东省药学科学院 | 一种2-[2-(6-溴己氧基)乙氧基甲基]-1,3-二氯苯的制备方法 |
CN115745945B (zh) * | 2022-11-15 | 2024-06-11 | 奥锐特药业股份有限公司 | 一锅法制备维兰特罗中间体的方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2140800A (en) | 1937-04-26 | 1938-12-20 | Metallurg De Hoboken Soc Gen | Treatment of substances containing tantalum and/or niobium |
US2918408A (en) | 1957-04-08 | 1959-12-22 | Lakeside Lab Inc | Anti-spasmodic compositions specific for treating spasm of the colon |
DE2140800C3 (de) | 1971-08-14 | 1980-10-16 | Industriewerk Schaeffler Ohg, 8522 Herzogenaurach | Loswalze für Streckwerke von Spinnmaschinen |
US3994974A (en) | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
CY1308A (en) | 1979-12-06 | 1985-12-06 | Glaxo Group Ltd | Device for dispensing medicaments |
CY1492A (en) | 1981-07-08 | 1990-02-16 | Draco Ab | Powder inhalator |
BR8305562A (pt) | 1982-10-08 | 1984-05-15 | Glaxo Group Ltd | Dispositivo para administrar medicamento a pacientes e embalagem |
GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
US4853381A (en) | 1984-04-17 | 1989-08-01 | Glaxo Group Limited | Ethanolamine compounds |
IL74940A (en) | 1984-04-17 | 1988-06-30 | Glaxo Group Ltd | Phenethanolamine compounds,their preparation and pharmaceutical compositions containing them |
DK173685A (da) | 1984-04-17 | 1985-10-18 | Glaxo Group Ltd | Ethanolaminderivater |
GB8426200D0 (en) | 1984-10-17 | 1984-11-21 | Glaxo Holdings Ltd | Chemical compounds |
LU86002A1 (fr) | 1984-07-13 | 1986-08-04 | Glaxo Group Ltd | Composes d'aminophenol |
AU591152B2 (en) | 1985-07-30 | 1989-11-30 | Glaxo Group Limited | Devices for administering medicaments to patients |
EP0223410A3 (en) | 1985-10-16 | 1987-11-19 | Glaxo Group Limited | Ethanolamine derivatives |
GB8525483D0 (en) | 1985-10-16 | 1985-11-20 | Glaxo Group Ltd | Chemical compounds |
EP0220054A3 (en) | 1985-10-16 | 1987-12-02 | Glaxo Group Limited | Ethanolamine derivatives |
FR2588474B1 (fr) | 1985-10-16 | 1987-11-27 | Cird | Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste |
US4937268A (en) | 1987-03-12 | 1990-06-26 | Glaxo Group Limited | Chemical compounds |
GB8718940D0 (en) | 1987-08-11 | 1987-09-16 | Glaxo Group Ltd | Chemical compounds |
GB8821179D0 (en) * | 1988-09-09 | 1988-10-12 | Glaxo Group Ltd | Chemical compounds |
IE883400L (en) * | 1987-11-13 | 1989-05-13 | Fuisz Technologies Ltd | Phenethanolamine derivatives |
GB2230523A (en) | 1989-04-14 | 1990-10-24 | Glaxo Group Ltd | 1-(3-Bromoisoxazol-5-yl)-2-aminoethanol derivatives |
GB8909273D0 (en) | 1989-04-24 | 1989-06-07 | Glaxo Group Ltd | Chemical compounds |
US5290815A (en) | 1989-09-07 | 1994-03-01 | Glaxo Group Limited | Treatment of inflammation and allergy |
IL95590A (en) | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
DE4028398A1 (de) | 1990-09-07 | 1992-03-12 | Thomae Gmbh Dr K | Phenylethanolamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
MX9301943A (es) | 1992-04-02 | 1994-08-31 | Smithkline Beecham Corp | Compuestos. |
GB9222700D0 (en) | 1992-10-29 | 1992-12-09 | Smithkline Beecham Plc | Chemical compounds |
GB9313574D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Medicaments |
GB9323429D0 (en) | 1993-11-12 | 1994-01-05 | Wellcome Found | Therapy |
AU1533495A (en) | 1994-01-12 | 1995-08-01 | Byk Nederland Bv | Phenyl ethanol amine ethers and uses thereof as beta-adreno-receptor agonists |
US5998428A (en) | 1995-05-31 | 1999-12-07 | Smithkline Beecham Corporation | Compounds and methods for treating PDE IV-related diseases |
US6632955B1 (en) | 1996-12-02 | 2003-10-14 | Chisso Corporation | Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same |
WO1999016766A1 (fr) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Derives de benzodioxole |
SI1070056T1 (en) | 1998-03-14 | 2004-12-31 | Altana Pharma Ag | Phthalazinone pde iii/iv inhibitors |
AR035987A1 (es) | 1999-03-01 | 2004-08-04 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
NZ517166A (en) | 1999-08-21 | 2004-01-30 | Altana Pharma Ag | Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonists |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
EP1366025B1 (en) | 2001-03-08 | 2007-06-27 | Glaxo Group Limited | Agonists of beta-adrenoreceptors |
CN103288793B (zh) | 2001-09-14 | 2015-09-23 | 葛兰素集团有限公司 | 治疗呼吸疾病的苯乙醇胺衍生物 |
GB0303396D0 (en) | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds |
US7351787B2 (en) * | 2004-03-05 | 2008-04-01 | Bioartificial Gel Technologies, Inc. | Process for the preparation of activated polyethylene glycols |
-
2002
- 2002-09-11 CN CN201310042387.2A patent/CN103288793B/zh not_active Expired - Lifetime
- 2002-09-11 CA CA2458534A patent/CA2458534C/en not_active Expired - Lifetime
- 2002-09-11 EP EP08170993.3A patent/EP2042168B1/en not_active Expired - Lifetime
- 2002-09-11 PT PT81709933T patent/PT2042168E/pt unknown
- 2002-09-11 AU AU2002326026A patent/AU2002326026B2/en active Active
- 2002-09-11 CN CN02822325XA patent/CN1585633B/zh not_active Expired - Lifetime
- 2002-09-11 KR KR1020097010537A patent/KR20090057477A/ko not_active Application Discontinuation
- 2002-09-11 CN CN200910208840.6A patent/CN101701006B/zh not_active Expired - Lifetime
- 2002-09-11 SI SI200230795T patent/SI1425001T1/sl unknown
- 2002-09-11 JP JP2003528536A patent/JP4191034B2/ja not_active Expired - Lifetime
- 2002-09-11 WO PCT/GB2002/004140 patent/WO2003024439A1/en active Application Filing
- 2002-09-11 RU RU2004106555/04A patent/RU2312854C2/ru active Protection Beyond IP Right Term
- 2002-09-11 NZ NZ531651A patent/NZ531651A/en not_active IP Right Cessation
- 2002-09-11 MX MXPA04002405A patent/MXPA04002405A/es active IP Right Grant
- 2002-09-11 PL PL393155A patent/PL393155A1/pl not_active Application Discontinuation
- 2002-09-11 DK DK08170993.3T patent/DK2042168T3/da active
- 2002-09-11 PL PL370276A patent/PL211953B1/pl not_active IP Right Cessation
- 2002-09-11 KR KR1020047003795A patent/KR100912324B1/ko active Protection Beyond IP Right Term
- 2002-09-11 ES ES08170993.3T patent/ES2438985T3/es not_active Expired - Lifetime
- 2002-09-11 US US13/719,797 patent/USRE44874E1/en not_active Expired - Lifetime
- 2002-09-11 BR BRPI0212455A patent/BRPI0212455B8/pt not_active IP Right Cessation
- 2002-09-11 DK DK02760407T patent/DK1425001T3/da active
- 2002-09-11 PT PT02760407T patent/PT1425001E/pt unknown
- 2002-09-11 AT AT02760407T patent/ATE417606T1/de active
- 2002-09-11 SI SI200231039T patent/SI2042168T1/sl unknown
- 2002-09-11 IL IL16059502A patent/IL160595A0/xx unknown
- 2002-09-11 US US10/489,569 patent/US7361787B2/en not_active Ceased
- 2002-09-11 ES ES02760407T patent/ES2316599T3/es not_active Expired - Lifetime
- 2002-09-11 EP EP02760407A patent/EP1425001B1/en not_active Expired - Lifetime
- 2002-09-11 HU HU0401619A patent/HU228508B1/hu active Protection Beyond IP Right Term
- 2002-09-11 DE DE60230425T patent/DE60230425D1/de not_active Expired - Lifetime
- 2002-09-12 TW TW091120875A patent/TWI299661B/zh active
- 2002-09-12 MY MYPI20023401A patent/MY129422A/en unknown
- 2002-09-13 AR ARP020103476A patent/AR036874A1/es active IP Right Grant
-
2004
- 2004-02-26 IL IL160595A patent/IL160595A/en active Protection Beyond IP Right Term
- 2004-03-10 CO CO04021965A patent/CO5560552A2/es active IP Right Grant
- 2004-03-11 NO NO20041041A patent/NO333813B1/no not_active IP Right Cessation
- 2004-11-30 HK HK04109440.3A patent/HK1066479A1/xx not_active IP Right Cessation
-
2006
- 2006-12-04 US US11/566,346 patent/US7439393B2/en active Active
-
2007
- 2007-06-28 RU RU2007124187/04A patent/RU2007124187A/ru not_active Application Discontinuation
-
2008
- 2008-09-16 US US12/211,322 patent/US7776895B2/en not_active Expired - Lifetime
-
2009
- 2009-02-25 CY CY20091100211T patent/CY1109422T1/el unknown
-
2010
- 2010-07-14 US US12/836,025 patent/US7982067B2/en not_active Expired - Lifetime
-
2011
- 2011-06-21 US US13/165,037 patent/US8198483B2/en not_active Expired - Fee Related
-
2013
- 2013-06-27 AR ARP130102285 patent/AR091595A2/es not_active Application Discontinuation
- 2013-12-16 CY CY20131101131T patent/CY1114728T1/el unknown
-
2014
- 2014-04-02 FR FR14C0028C patent/FR14C0028I2/fr active Active
- 2014-04-03 NO NO2014007C patent/NO2014007I1/no not_active IP Right Cessation
- 2014-04-24 HU HUS1400025C patent/HUS1400025I1/hu unknown
- 2014-04-25 BE BE2014C026C patent/BE2014C026I2/fr unknown
- 2014-04-28 CY CY2014019C patent/CY2014019I1/el unknown
- 2014-04-30 LU LU92439C patent/LU92439I2/fr unknown